Contact
searchSearch
HMP Global

Advertisement

ADVERTISEMENT

Multiple Sclerosis News

News
Addressing Health Equity for Multiple Sclerosis Management in Diverse Patient Populations
08/16/2021
Clyde E. Markowitz, MD, discussed the racial disparities in treatment for multiple sclerosis (MS) and a need to individualize treatment based on patient considerations, during a virtual bonus presentation at Neurology Week.
Clyde E. Markowitz, MD, discussed the racial disparities in treatment for multiple sclerosis (MS) and a need to individualize treatment based on patient considerations, during a virtual bonus presentation at Neurology Week.
Clyde E. Markowitz, MD,...
08/16/2021
Neurology

Advertisement

News
Lipid-Specific IgM Oligoclonal Bands Can Predict Aggressive Multiple Sclerosis Early
08/11/2021
Intrathecal immunoglobulin M synthesis (ITMS), a biomarker for poor prognosis in patients with multiple sclerosis (MS), can predict aggressive MS at disease onset when detected by lipid-specific IgM oligoclonal bands (LS-OCMBs), according to...
Intrathecal immunoglobulin M synthesis (ITMS), a biomarker for poor prognosis in patients with multiple sclerosis (MS), can predict aggressive MS at disease onset when detected by lipid-specific IgM oligoclonal bands (LS-OCMBs), according to...
Intrathecal immunoglobulin M...
08/11/2021
Neurology
News
Ocrelizumab Effective at Controlling Relapse in Patients with Multiple Sclerosis
08/05/2021
Ocrelizumab is an effective treatment option to control relapse risk and disability worsening in patients with multiple sclerosis (MS), according to recent findings published in BMJ Neurology Open.
Ocrelizumab is an effective treatment option to control relapse risk and disability worsening in patients with multiple sclerosis (MS), according to recent findings published in BMJ Neurology Open.
Ocrelizumab is an effective...
08/05/2021
Neurology
Conference Coverage
Unmet Needs and the Evolving Treatment Landscape of Multiple Sclerosis
07/28/2021
Benjamin Greenberg, MD, MHS, discussed the unmet needs and upcoming developments in the diagnosis and treatment of multiple sclerosis (MS) during a virtual presentation given at Neurology Week.
Benjamin Greenberg, MD, MHS, discussed the unmet needs and upcoming developments in the diagnosis and treatment of multiple sclerosis (MS) during a virtual presentation given at Neurology Week.
Benjamin Greenberg, MD, MHS,...
07/28/2021
Neurology

Advertisement

News
Choice of Disease Modifying Therapy May Impact Depression Risk for Multiple Sclerosis
07/23/2021
Choice of disease modifying therapy for patients with multiple sclerosis (MS) is associated with risk of depression, according to new research published in Multiple Sclerosis Journal.
Choice of disease modifying therapy for patients with multiple sclerosis (MS) is associated with risk of depression, according to new research published in Multiple Sclerosis Journal.
Choice of disease modifying...
07/23/2021
Neurology
News
High Efficacy Therapies Reduce Relapses in Secondary Progressive Multiple Sclerosis
07/23/2021
High-efficacy therapies are more effective at reducing relapse for patients with secondary progressive multiple sclerosis (MS) than low-efficacy therapies, according to new research published in Neurology.
High-efficacy therapies are more effective at reducing relapse for patients with secondary progressive multiple sclerosis (MS) than low-efficacy therapies, according to new research published in Neurology.
High-efficacy therapies are more...
07/23/2021
Neurology
News
Disease Modifying Therapies Improve Prognosis in Patients with Pediatric-Onset Multiple Sclerosis
06/25/2021
The risk of reaching persistent disability in patients with pediatric-onset multiple sclerosis (MS) has seen a significant reduction amidst increases of approved disease modifying therapies before age 18, which will continue to improve future...
The risk of reaching persistent disability in patients with pediatric-onset multiple sclerosis (MS) has seen a significant reduction amidst increases of approved disease modifying therapies before age 18, which will continue to improve future...
The risk of reaching persistent...
06/25/2021
Neurology

Advertisement

News
Intrathecal Immunoglobulin M Synthesis Predicts Disease Activity and Severity in Multiple Sclerosis
06/10/2021
Intrathecal Immunoglobulin M synthesis is a biomarker for disease activity and severity in patients with relapsing multiple sclerosis (MS), suggests results published in Annals of Neurology.
Intrathecal Immunoglobulin M synthesis is a biomarker for disease activity and severity in patients with relapsing multiple sclerosis (MS), suggests results published in Annals of Neurology.
Intrathecal Immunoglobulin M...
06/10/2021
Neurology
News
Scientists Identify Multiple Sclerosis Subtypes, Predict Progression and Treatment Response Using Artificial Intelligence
05/12/2021
MRI-based subtypes identified by unsupervised machine learning algorithms can be used to predict disease progression and response to treatment in patients with multiple sclerosis, according to findings from scientists at University College...
MRI-based subtypes identified by unsupervised machine learning algorithms can be used to predict disease progression and response to treatment in patients with multiple sclerosis, according to findings from scientists at University College...
MRI-based subtypes identified by...
05/12/2021
Neurology
News
Alternative Natalizumab Dosing Regimen Safe, Effective for Relapsing-Remitting Multiple Sclerosis
04/30/2021
Researchers have found an alternative natalizumab administration route for patients with relapsing-remitting multiple sclerosis (RRMS), according to a prospective phase 2 study.
Researchers have found an alternative natalizumab administration route for patients with relapsing-remitting multiple sclerosis (RRMS), according to a prospective phase 2 study.
Researchers have found an...
04/30/2021
Neurology

Advertisement

Advertisement

Advertisement

News

Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
News
Semaglutide May Lower Risk of Alzheimer Disease in Patients With Type 2 Diabetes
11/05/2024
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes and obesity prescribed semaglutide had a 40% to 70% lower risk of a first-time Alzheimer disease (AD) diagnosis compared with patients taking other antidiabetic medications, according to a study published in...
Patients with type 2 diabetes...
11/05/2024
Psych Congress Network
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
News
Alone or Together, CBT and Modafinil Improve MS-Related Fatigue
11/01/2024
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug modafinil, CBT, and a combination of both were associated with comparable, significant improvement in fatigue at 12 weeks in patients with MS and problematic fatigue.
The wake-promoting drug...
11/01/2024
Neurology
Gene therapy
News
Concerns Linger After Gene Therapy Shows Long-Term Benefit for Cerebral Adrenoleukodystrophy
10/28/2024
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel (eli-cel) gene therapy for cerebral adrenoleukodystrophy (CALD) helped patients maintain neurological function, but also my have caused hematologic malignancies in some patients.
Elivaldogene autotemcel...
10/28/2024
Neurology
Patient with family
News
During Recovery, Stroke Patients Benefit from Supportive Social Networks
10/24/2024
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and friends are beneficial for blood pressure improvement among patients who experienced a stroke, according to a study published online in the International Journal of Cerebrovascular Disease and Stroke. “In aging...
Large networks of family and...
10/24/2024
Neurology
International Stroke Burden Saw Hike Over Last 30 Years
News
International Stroke Burden Saw Hike Over Last 30 Years
10/22/2024
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has increased from 1990 to 2021, according to recent findings from a global burden of disease (GBD) study published in The Lancet Neurology.
International stroke burden has...
10/22/2024
Neurology
Hands holding a head in profile with an illustrated heart over brain
News
Antiseizure Meds May Increase Cardiovascular Risk in Older Adults With Epilepsy
10/21/2024
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy is associated with new-onset cardiovascular events in older adults, according to study results published in JAMA Neurology.
A lifetime history of epilepsy...
10/21/2024
Neurology
FDA approval stamp
News
FDA Approves Infusion Treatment for Advanced Parkinson Disease in Adults
10/18/2024
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa and foslevodopa), the first 24-hour continuous subcutaneous infusion of levodopa-based therapy for managing motor fluctuations in adults with advanced Parkinson disease (PD), approved by the FDA.
AbbVie’s VYALEV (foscarbidopa...
10/18/2024
Neurology
Investigational Drug Improves Motor Function in Patients With SMA
News
Investigational Drug Improves Motor Function in Patients With SMA
10/16/2024
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational muscle-targeted therapy, improved motor function in patients with spinal muscular atrophy (SMA), late-stage biopharmaceutical company Scholar Rock recently announced.
Apitegromab, an investigational...
10/16/2024
Neurology
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
News
Tolebrutinib Delays Disability Progression in Nonrelapsing Secondary Progressive MS
10/15/2024
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to onset of 6-month confirmed disability progression compared with placebo in patients with nonrelapsing secondary progressive MS, according to results presented at the European Committee for Treatment and...
Tolebrutinib delayed the time to...
10/15/2024
Neurology
An orange prescription container with generic pills spilling out in front of it
News
Masked Taper Plus CBT for Insomnia Effective in Benzodiazepine Discontinuation
10/10/2024
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined with cognitive behavioral therapy for insomnia (CBTI) were associated with improved benzodiazepine receptor agonist discontinuation in patients receiving treatment for insomnia
A masked drug taper combined...
10/10/2024
Psych Congress Network

Advertisement

Advertisement

Alzheimer's Disease CME Series

Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources To view accreditation information/faculty disclosures for the program, click 
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesOnline Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient Resources
11/19/2020
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease: Caregiver Connections, Shared Decision Making, and Patient ResourcesTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click...
Early Alzheimer’s Disease:...
11/19/2020
Neurology
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer Disease: Efficacy and Safety Data To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data Online Form - PBHLN-NLN Alzheimers Video Series
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety Data
11/17/2020
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early Alzheimer’s Disease: Efficacy and Safety DataTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation...
Emerging Treatments for Early...
11/17/2020
Neurology
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action To view accreditation information/faculty disclosures for the program, click 
Emerging Treatments for Early...
11/12/2020
Neurology
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology
11/12/2020
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease Overview: Burden of Disease, Quality-of-Life Impacts, and Pathophysiology Online Form - PBHLN-NLN Alzheimers Video Series
Early Alzheimer’s Disease...
11/12/2020
Neurology
Claim-Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of Action
11/12/2020
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early Alzheimer’s Disease: Mechanisms of ActionTo claim credit for the program, click HERE for the evaluation. You will need to log in or create an account with NACCME, and then click on the evaluation button...
Emerging Treatments for Early...
11/12/2020
Neurology
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease
11/10/2020
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations and Clinical Needs in Early Alzheimer’s Disease To view accreditation information/faculty disclosures for the program, click 
Current Treatment Limitations...
11/10/2020
Neurology

Advertisement

Advertisement

Advertisement

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use